Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michael Ulitzka"'
Publikováno v:
Molecules, Vol 29, Iss 5, p 1140 (2024)
Valued for their ability to rapidly kill multiple tumor cells in succession as well as their favorable safety profile, NK cells are of increasing interest in the field of immunotherapy. As their cytotoxic activity is controlled by a complex network o
Externí odkaz:
https://doaj.org/article/68cfee385c1a47cf8094176669399c9c
Autor:
Julia Harwardt, Jan P. Bogen, Stefania C. Carrara, Michael Ulitzka, Julius Grzeschik, Björn Hock, Harald Kolmar
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Various formats of bispecific antibodies exist, among them Two-in-One antibodies in which each Fab arm can bind to two different antigens. Their IgG-like architecture accounts for low immunogenicity and also circumvents laborious engineering and puri
Externí odkaz:
https://doaj.org/article/baa198aa1ffd4bf4a0f536479913b5c4
Autor:
Julius Grzeschik, Björn Hock, Harald Kolmar, Michael Ulitzka, Stefania C. Carrara, Henri Kornmann
Publikováno v:
Protein Engineering, Design and Selection. 33
Established monoclonal antibodies (mAbs) allow treatment of cancers, autoimmune diseases and other severe illnesses. Side effects either arise due to interaction with the target protein and its biology or result from of the patient’s immune system
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1e367e7579ee94f91f9aa18be538cdb
https://doi.org/10.1093/protein/gzaa025
https://doi.org/10.1093/protein/gzaa025